[Pharmacokinetics of cefodizime in patients undergoing hemodialysis]

Jpn J Antibiot. 1991 Dec;44(12):1392-6.
[Article in Japanese]

Abstract

The object of this study was to establish the most effective regimen of cefodizime (CDZM) for patients with chronic renal failure undergoing hemodialysis (HD). T 1/2 beta of CDZM upon 1 g intravenous administration was 3.50 +/- 0.72 hours in an on-HD group, and it was 11.26 +/- 3.89 hours in an off-HD group. When CDZM was administered consecutively at a dose of 1 g or 2 g only after HD, the serum concentration of CDZM was maintained at levels sufficient to exert antibacterial activity, and no tendency for accumulation was observed. The most effective regimen of CDZM to HD patients, therefore, has been that in which concluded to administration was done only after completion of HD, in a dose of 1 g for mild infections and that of 2 g for severe infections.

Publication types

  • English Abstract

MeSH terms

  • Cefotaxime / administration & dosage
  • Cefotaxime / analogs & derivatives*
  • Cefotaxime / blood
  • Cefotaxime / pharmacokinetics
  • Dialysis Solutions / analysis
  • Humans
  • Injections, Intravenous
  • Kidney Failure, Chronic / metabolism
  • Kidney Failure, Chronic / therapy
  • Renal Dialysis*

Substances

  • Dialysis Solutions
  • Cefotaxime
  • cefodizime